<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710615</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2019/33</org_study_id>
    <nct_id>NCT04710615</nct_id>
  </id_info>
  <brief_title>Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults</brief_title>
  <acronym>PING</acronym>
  <official_title>Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polypharmacy in the older adults is common and promotes the risk of drug interactions. The&#xD;
      hypothesis evoked is that a virtual platform with artificial intelligence applied to the&#xD;
      health, and in particular to the good use of the drug, could bring aids to the doctors them&#xD;
      of the prescription of drugs. The main objective of this study is to evaluate the impact of&#xD;
      geriatric use of the Synapse platform on the frequency of inappropriate medication&#xD;
      prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older&#xD;
      hospitalized in geriatric department.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The French 2018-2022 National Health Strategy plan aims to reduce the proportion of&#xD;
      potentially harmful medication use. One particular challenge is the phenomenon of&#xD;
      polypharmacy and inappropriate medication use in elderly, which is associated to an increased&#xD;
      risk of drug-drug interactions. Several scales and tools have been proposed to identify&#xD;
      inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria&#xD;
      (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment)&#xD;
      are internationally recognized.&#xD;
&#xD;
      The Synapse platform offers a panel of functions that may help physicians to prescribe&#xD;
      medications. For instance, the prescriber can interact with the Synapse platform by asking&#xD;
      any type of question about a drug (dosage, contraindication, interaction ...) before&#xD;
      prescription. It also allows them to take a picture of prescription. The software detects in&#xD;
      less than 10 seconds criteria for inappropriate medication prescriptions and potential&#xD;
      drug-drug interactions.&#xD;
&#xD;
      More precisely, the Synapse platform provides information on a particular drug or&#xD;
      prescription analysis regarding:&#xD;
&#xD;
        -  Indications, contraindications, dosage and adverse effects of drugs.&#xD;
&#xD;
        -  STOPP criteria.&#xD;
&#xD;
        -  START criteria.&#xD;
&#xD;
        -  Associations at risk for drug-drug interactions.&#xD;
&#xD;
      Multiple new health technologies are emerging, but few of them have demonstrated their&#xD;
      scientific and medical added value using an evidence-based medicine approach.&#xD;
&#xD;
      This clinical trial aims to validate the clinical interest of the Synapse application in a&#xD;
      geriatric environment.&#xD;
&#xD;
      Prescriptions made by geriatricians participating in this study will be analyzed by two&#xD;
      independent experts, including one pharmacist and one geriatrician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with decrease in STOPP criteria number between initial prescription and exist prescription.</measure>
    <time_frame>Month 6</time_frame>
    <description>Proportion of patients with decrease in STOPP criteria number between initial prescription and exist prescription.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with increase in START criteria number between initial prescription and exist prescription.</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of patients with increase in START criteria number between initial prescription and exist prescription.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with increase in START criteria number between initial prescription and exist prescription.</measure>
    <time_frame>Month 6</time_frame>
    <description>Proportion of patients with increase in START criteria number between initial prescription and exist prescription.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of STOPP criteria</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference in the number of STOPP criteria between initial and discharge prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of STOPP criteria</measure>
    <time_frame>Month 6</time_frame>
    <description>Difference in the number of STOPP criteria between initial and discharge prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of START criteria</measure>
    <time_frame>Day 1</time_frame>
    <description>Difference in the number of START criteria between initial and discharge prescription.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of START criteria</measure>
    <time_frame>Month 6</time_frame>
    <description>Difference in the number of START criteria between initial and discharge prescription.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with decrease in contraindicated drug-drug interaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with decrease in contraindicated drug-drug interaction</measure>
    <time_frame>Month 6</time_frame>
    <description>Proportion of patients with decrease in contraindicated drug-drug interaction number between initial and discharge prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with decrease if active pharmaceutical ingredients</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with decrease if active pharmaceutical ingredients</measure>
    <time_frame>Month 6</time_frame>
    <description>Proportion of patients with decrease in number of active pharmaceutical ingredients between initial and discharge prescription</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of connections per week on Synapse platform by geriatricians</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of connections per week on Synapse platform by geriatricians</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Drug-drug Interactions</condition>
  <condition>Geriatric Disease</condition>
  <arm_group>
    <arm_group_label>Assistance device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With prescription assistance device:&#xD;
During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No device</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, …</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synapse platform</intervention_name>
    <description>The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.&#xD;
The Synapse platform offers a panel of functions to help the doctor to prescribe medication.</description>
    <arm_group_label>Assistance device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria:&#xD;
&#xD;
               -  Male or female age aged more than 65 years&#xD;
&#xD;
               -  Hospitalization in geriatric department at Bordeaux University Hospital or&#xD;
                  Libourne Hospital&#xD;
&#xD;
               -  Initial drug prescription with at least 2 active pharmaceutical ingredients&#xD;
&#xD;
               -  Affiliation to French social security&#xD;
&#xD;
               -  Written informed consent signed by participant and investigator&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               -  Adults protected by law&#xD;
&#xD;
               -  Subject included in a clinical trial with an experimental treatment&#xD;
&#xD;
               -  Subject during exclusion period relative to another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Olivier GIRODET, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Olivier GIRODET, MD, PhD</last_name>
    <phone>+335 57 57 15 60</phone>
    <email>pierre-olivier.girodet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karelle FOREST</last_name>
    <phone>+335 57 57 46 66</phone>
    <email>karelle.forest@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux, Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire ROUBAUD-BAUDRON, MD, PhD</last_name>
      <phone>+335 56 82 18 44</phone>
      <email>claire.roubaud@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Claire ROUBAUD-BAUDRON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BONNET, MD, PhD</last_name>
      <phone>+335 56 79 58 26</phone>
      <email>fabrice.bonnet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice BONNET, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Libourne - Pôle Gériatrie</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa ESTAQUE, MD</last_name>
      <phone>+335 57 55 16 03</phone>
      <email>elsa.estaque@ch-libourne.fr</email>
    </contact>
    <investigator>
      <last_name>Elsa ESTAQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux, Hôpital Xavier Arnozan</name>
      <address>
        <city>Pessac</city>
        <zip>33400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire ROUBAUD-BAUDRON, MD, PhD</last_name>
      <phone>+335 56 82 18 44</phone>
      <email>claire.roubaud@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Claire ROUBAUD-BAUDRON, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux, Hôpital Xavier Arnozan</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie SALLES, MD, PhD</last_name>
      <phone>+335 57 65 65 53</phone>
      <email>nathalie.salles@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Nathalie SALLES, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drugs</keyword>
  <keyword>artificial</keyword>
  <keyword>intelligence</keyword>
  <keyword>medications</keyword>
  <keyword>Elderly</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

